← Open Payments lookup

NPI 1730756461: Open Payments

NPI 1730756461. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.

See the full provider profile for registry, prescribing and billing details.

Industry payments (Sunshine Act)

Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.

$1,010 in 52 payments from 17 companies in 2025. Trend: 2023 $1,104 · 2024 $632 · 2025 $1,010

Food & beverage: $1,010
CompanyPaymentsAmount
Novo Nordisk Inc13$228
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)11$158
ABBVIE INC.4$87
Lundbeck LLC4$81
Vanda Pharmaceuticals Inc.3$81
Axsome Therapeutics, Inc.3$67
Viatris Specialty LLC2$65
Exact Sciences Corporation2$38
Corcept Therapeutics2$35
Amgen Inc.1$31

Products named: CAPLYTA, Wegovy, REXULTI, FANAPT, Auvelity, VRAYLAR, YUPELRI, Ozempic.